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ABSTRACT
Intensive chemotherapy followed by autologous stem cell transplantation is the treatment of
choice for patients with hematological malignancies. The objective of the present study was to evaluate the outcomes of patients with mainly lymphoma and multiple myeloma after autologous stem
cell transplant. The pretransplant workup consisted of the complete blood count, an evaluation of
the liver, kidney, lung, and infectious profile, chest radiographs, and a dental review. For lymphoma,
all patients who achieved at least a 25% reduction in the disease after salvage therapy were included
in the study. Mobilization was done with cyclophosphamide, followed by granulocyte colonystimulating factor, 300 mg twice daily. The conditioning regimens included BEAM (carmustine,
etoposide, cytarabine, melphalan) and high-dose melphalan. A total of 206 transplants were performed from April 2004 to December 2014. Of these, 137 were allogeneic transplants and 69 were
autologous. Of the patients receiving an autologous transplant, 49 were male and 20 were female.
Of the 69 patients, 26 underwent transplantation for Hodgkin’s lymphoma, 23 for non-Hodgkin’s lymphoma, and 15 for multiple myeloma and 4 and 1 for Ewing’s sarcoma and neuroblastoma, respectively.
The median age 6 SD was 34 6 13.1 years (range, 4–64). A mean of 4.7 3 108 6 1.7 mononuclear cells
per kilogram were infused. The median time to white blood cell recovery was 18.2 6 5.34 days.
Transplant-related mortality occurred in 10 patients. After a median follow-up period of 104 months,
the overall survival rate was 86%. High-dose chemotherapy, followed by autologous stem cell transplant, is an effective treatment option for patients with hematological malignancies, allowing further
consolidation of response. STEM CELLS TRANSLATIONAL MEDICINE 2015;4:873–877

http://dx.doi.org/
10.5966/sctm.2015-0015

SIGNIFICANCE
This report presents the results of autologous stem cell transplant in hematological malignancies
from a developing country. This is a large cohort from Pakistan, with overall survival comparable
to that from international data.

INTRODUCTION
Autologous stem cell transplantation (ASCT) is
an alternative treatment modality for lymphomas, multiple myeloma, and a few solid tumors
[1]. In the 1970s, it was postulated that stem cell
mobilization was possible after a high level of
progenitor cells were observed in the blood of
patients who had received cyclophosphamide
chemotherapy [2]. In 1984, the CD34 marker was
identified on hematopoietic stem cells. This second
discovery led to a swift increase in the understanding and manipulation of ASCT, which resulted in its
significant growth [3].
Autologous hematopoietic stem cell transplantation (HSCT) is used to bridge hematopoietic
failure during high-dose chemotherapy for the
treatment of tumors of the hematopoietic system
that are adequately sensitive to this treatment. In
this sense, autologous stem cell support is not a

“transplant”; however, the term “autologous HSCT”
is commonly used. This procedure was initially developed for patients with leukemia without a sibling
donor for allogeneic transplant. Later, it became
the standard of care for patients with lymphoma,
myeloma, and some childhood neoplasms [4].
More than one half of the stem cell transplants
performed in Europe are autologous. The European
Bone Marrow Transplant (EBMT) annual activity survey for 2011 reported a 58% rate of autologous stem
celltransplants.MostoftheseASCTswereperformed
for lymphoid malignancies (plasma cell disorders,
46%; non-Hodgkin’s lymphoma, 30%; Hodgkin’s disease, 11%). The focus from marrow to peripheral
blood as a source of stem cells occurred in the early
1990s for ASCT. Recent data now suggest that 99% of
all autologous transplant procedures use peripheral
blood as the source [5].
The 2011 Center for International Blood and
Bone Marrow Transplant Research (CIBMTR) data
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showed that 12,047 autologous transplants were performed, for
which multiple myeloma and lymphomas were the most common
indications [6].
The standard treatment for B-cell non-Hodgkin’s lymphoma
(NHL) includes chemotherapy with rituximab.
A Cochrane analysis published in 2013 evaluated 2 randomized control trials (n = 157) of relapsed Hodgkin’s lymphoma
(HL) patients that included 2 treatment arms: high-dose chemotherapy (HDCT) plus autologous stem cell transplantation versus
conventional chemotherapy without autologous stem cell transplantation. The difference in progression-free survival was statistically significant for patients treated with HDCT followed
by ASCT compared with patients treated with conventional chemotherapy alone (hazard ratio [HR], 0.55; 95% confidence interval [CI] 0.35–0.86; p = .009) [7].
Two systematic reviews assessed the efficacy of high-dose
chemotherapy with single ASCT versus conventional chemotherapy in patients with multiple myeloma. The pooled results have
shown a statistically nonsignificant difference in survival between
high-dose chemotherapy plus stem cell rescue (HR, 0.92; 95%
CI, 0.74–1.13; p = .40) versus chemotherapy. For the outcome
of progression-free survival, a statistically significant benefit was
associated with high-dose chemotherapy plus stem cell rescue
(HR, 0.75; 95% CI, 0.59–0.96; p = .02) [8].
Kumar et al. [9] in a study from India in 2010 reported a median overall and event-free survival of 78 and 28 months, respectively, for patients undergoing autologous stem cell transplant for
Hodgkin’s and non-Hodgkin’s lymphoma.
In Pakistan, use of the hematopoietic stem cell transplant
procedure started in 1995. Because of the burden of nonmalignant diseases such as b-thalassemia major and aplastic anemia, the number of allogeneic transplants have outnumbered
the number of autologous transplant procedures. Nevertheless, we have a significant burden of lymphoid malignancies
in young patients for whom autologous hematopoietic transplantation is the only curative option. In the present report,
we present our initial data on the frequency and outcomes
of autologous stem cell transplants performed in our center
from 2004 to 2014.

MATERIALS AND METHODS
We retrospectively analyzed the data from all patients who underwent autologous stem cell transplant from April 2004 to
December 2014. The patients were considered to have chemosensitive disease if they had had a complete response (CR) or partial remission at ASCT. These included patients with HL, NHL, and
multiple myeloma. Patients with a minimal response (25%–50%
response), progressive, or refractory disease were considered
to have chemoresistant disease.
Our institute is a tertiary care, private hospital with 29 beds
dedicated to cancer patients. In addition, 54 beds are available
in a day care center exclusively for hematology/oncology patients
for chemotherapy administration and blood and/or blood product transfusion. The transplant unit was established in 2004
and was initially a 2-bed facility that was upgraded to 4 beds later.
Pakistan’s gross domestic product in 2013 was reported to be
$232.3 billion. The average household income ranges from
$1,200 to $1,500 annually. Therefore, affording an expensive procedure such as stem cell transplant is very challenging. Nevertheless, the cost of the procedure is met by the patients themselves,
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philanthropists, and medical insurance. Patients are referred for
transplant from all over the country. All patients are initially
assessed at outpatient clinics. The patients and their family members are counseled about the procedure and the potential risks
and benefits. Post-transplant patients are followed up initially
monthly for 3 months, every 3 months for 1 year, and every
6 months thereafter. Some of our patients come from outside
the city or country. These patients are followed up locally by
the referring oncologist or hematologist. If required, communication was maintained through electronic mail and telephone.
The pretransplant evaluation included the complete blood
count, liver and kidney function tests, infectious disease profile
(i.e., hepatitis B surface antigen, hepatitis C antibody, HIV antibody,
cytomegalovirus, Mantoux test, and chest radiography), blood
group determination and coagulation testing, pulmonary function
tests, echocardiography, and a dental evaluation. A central line
(Hickman’s catheter) was inserted in all patients. All the patients
were admitted to a single room, and reverse barrier nursing was
practiced. The patients provided written informed consent for chemotherapy, blood product administration, and transplantation.
Mobilized peripheral blood stem cells (PBSCs) were harvested
from all the patients. For mobilization, the patients received cyclophosphamide 1.5 g/m2 followed by granulocyte colony-stimulating
factor (G-CSF) 5 mg/kg twice daily subcutaneously for 6 days. The
stem cells were harvested on days 5 to 7 using either the Cobe Spectra AutoPBSC or COMTEC (Fresenius Kabi, Bad Homberg, Germany,
https://www.terumobct.com) system and the default software
configuration recommended by the manufacturer. The mononuclear cells were counted manually.
For multiple myeloma, the patients received high-dose melphalan (200 mg/m2). For patients with HL and NHL, carmustine
(BCNU; 300 mg/m2), etoposide (200 mg/m2), cytarabine (ara-C;
200 mg/m2), and melphalan (140 mg/m2) were used.
Patients were admitted to a single room with a high-efficiency
particulate air (HEPA) filter. Standard prophylaxis with ciprofloxacin (500 mg twice daily or 20–30 mg/kg in 2 divided doses),
fluconazole (200 mg once daily or 6 mg/kg per day), and valaciclovir (500 mg twice daily or 10 mg/kg twice daily) was started in all
patients on day 25. All patients were provided a neutropenic diet.
The autologous stem cells were reinfused on day 0 through the
central venous catheter and preceded by i.v. pheniramine maleate (50 mg). G-CSF, 5 mg/kg, was started on day +1. All patients
received irradiated blood products. All packed red blood cell
transfusions were performed with a leukocyte filter, and febrile
neutropenia evaluations and treatment were performed in accordance with the standard guidelines.
Engraftment was defined as achievement of an absolute neutrophil count of $0.5 3 109 per liter for 3 consecutive days. Platelet engraftment was defined as a count of $20 3 109 per liter with
transfusion independence. Patients were evaluated for response
using the World Health Organization criteria at 4 weeks after
transplant at the outpatient clinic with subsequent follow-up
examinations. In patients with multiple myeloma, the response
was assessed and monitored using serial immunoglobulin levels.
Patients with Ewing’s sarcoma or neuroblastoma were excluded from the analysis because of insufficient patient numbers.
The remaining patients were evaluable for the response and survival analyses. Overall survival was defined as that from the date
of transplant until death or the date of the last follow-up visit. The
curve for overall survival was plotted according to Kaplan and
Meier. Statistical analysis was performed using SPSS software,
S TEM C ELLS T RANSLATIONAL M EDICINE
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version 19.0 (IBM Corp., Armonk, NY, http://www-01.ibm.com/
software/analytics/spss/).

RESULTS
In the study period, a total of 206 hematopoietic stem cell transplants
were performed at our center. Of these, 69 were autologous transplants. Of the patients with lymphoma, 2 underwent the procedure
in the first CR. All others achieved more than a 50% response to salvage chemotherapy and underwent the procedure in the second CR.
Hodgkin’s disease was the most common indication (n = 26, 38%) followed by non-Hodgkin’s lymphoma (n = 23, 33%), multiple myeloma
(n = 15, 22%), Ewing’s sarcoma (n = 4, 6%), and neuroblastoma (n = 1).
Owing to the small numbers, the patients with Ewing’s sarcoma and
neuroblastoma were excluded from the analysis. Before transplantation, all patients had chemosensitive disease. The salvage regimens
for the patients with lymphoma included dexamethasone, Ara-C, and
cisplatin in 29 patients, ifosfamide, carboplatin, and etoposide in 16
patients, and etoposide, methylprednisolone, cytarabine, and cisplatin in 4 patients. All 15 patients with multiple myeloma underwent the procedure in the plateau phase. The median age 6 SD
was 34 6 13.1 years (range, 4–64). Of the 69 patients, 5 were in the
pediatric age group and the rest were adults (49 men and 20 women).
The peripheral blood stem cells were infused in 67 patients, and
2 patients received both peripheral and bone marrow progenitor
stem cells. A mean of 4.7 3 108 6 1.7 mononuclear cells per kilogram (range, 2.2–10) were infused. Of the 69 patients, 64 achieved
engraftment (93%), and 5 had primary graft failure, mainly because
of sepsis. The median time to white blood cell recovery was 18.2 6
5.34 days (range, 12.9–23.5). The median time to platelet transfusion independence was 15 days (range, 12–40). The median duration
of antibiotic therapy secondary to febrile neutropenia was 13 days.
Thehospitalstaywasrangedfrom 11 to52days(median6SD, 286 8).
A total of 149 febrile episodes were documented in 41 patients.
Central line-associated bloodstream infections were present in
12 patients. The common organisms were Staphylococcus species
and Escherichia. coli. Ten patients developed bloodstream infections (BSIs). The most common organism was E. coli (Fig. 1). During
the hospital stay, 13 patients (19%) required intensive care unit admission. In 1 patient, the sputum culture and sensitivity testing was
positive for Aspergillus flavus. The computed tomography scan of
the chest showed a fungal ball that was subsequently removed surgically. Transplant-related mortality for all evaluable patients was
15%. The cause of death for transplant-related mortality was
mainly sepsis (Table 1). After a median follow-up of 104 months,
the overall survival rate was 86% (Fig. 2). One transplant-related
mortality (TRM) occurred in a patient with multiple myeloma,
and the overall survival was 93%. For patients with non-Hodgkin’s
lymphoma, the TRM rate was 25% and the overall survival rate was
approximately 70%. The TRM for patients with Hodgkin’s disease
was 12%. The overall survival for these patients was 71%. The overall survival according to the diagnosis is shown in Figure 3.

DISCUSSION
The rationale of the present study was to compile data on the frequency, complications, and overall survival after autologous
transplant performed in the past decade at our center. The two
main indications were lymphoma and multiple myeloma, in accordance with the frequency reported from the CIBMTR, EBMT, and
India [10]. The use of PBSCs for autologous and allogeneic transplantation has increased significantly in recent years. According to the
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Figure 1. Frequency of CLABSI and BSI organisms. Abbreviations:
BSI, bloodstream infection; CLABSI, central line-associated bloodstream infection.
Table 1. Causes of transplantation-related mortality
Pt. No.

Age (yr)

Diagnosis

1

62

NHL

Toxicity

2

35

HL

Sepsis

3

49

HL

Sepsis, ARDS, cardiomyopathy

4

52

NHL

Acute renal and liver failure,
graft failure

5

59

HL

6

42

NHL

Sepsis, MOF

7

45

NHL

Sepsis, ARF

8

20

NHL

Pneumonia, respiratory
failure, graft failure

9

39

MM

Sepsis, graft failure

10

24

HL

Sepsis, graft failure

Sepsis, NSTEMI, cardiogenic
shock, graft failure

Sepsis

Abbreviations: ARDS, acute respiratory distress syndrome; ARF, acute
renal failure; HD, Hodgkin’s lymphoma; MM, multiple myeloma; MOF,
multiorgan failure; NHL, non-Hodgkin’s lymphoma; NSTEMI,
non-ST-segment elevation myocardial infarction; Pt. No., patient number.

CIBMTR, in more than 95% of autologous stem cell transplants, mobilized PBSC are used. The advantages of using PBSCs include a shorter
engraftment time, fewer transfusions, a shorter hospital stay, the
convenience of stem cell collection, and rapid restoration of the
immune system [11]. In 97% of our patients, PBSCs were used. In
the 2 patients who had received bone marrow stem cells, no difference was found in the engraftment time or hospital stay. The
relatively late engraftment resulted from the late presentation
and pretreatment with high doses of cytotoxic chemotherapy in these
patients. Five patients experienced primary graft failure and multiple organ failure, which contributed to the overall mortality. Most
of these deaths were in the initial years of the transplant program.
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Figure 2. Overall survival.

Figure 3. Overall survival according to diagnosis.

Once the learning curve had been completed, the mortality rate
decreased from 21% in 2004–2009 to 8% in 2010–2014. The
median 6 SD age was 34 6 13.1 years. Studies reported from
the region have shown the median age to be 45 years, in particular,
for NHL [12]. Our study reported a much younger age of presentation. This younger age group preponderance has been reported
previously in other hematological and nonhematological malignancies [13–15] from our region, consolidating that cancer, in
our population, has a predilection for a younger population.
The major gastrointestinal toxicities observed were grade III
to IV nausea/vomiting, diarrhea, and mucositis. These toxicities
were higher in patients with multiple myeloma owing to the
high-dose melphalan conditioning therapy. The incidence of organ toxicities (e.g., real dysfunction [16], veno-occlusive disease
[17], and pulmonary [18], cardiac [19], and central nervous system
toxicity [20]) was similar to that reported in published studies and
did not differ according to the type of conditioning therapy used.
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In the present study, 7% of patients died of regimen-related
toxicity. The CIBMTR data reported 12% mortality from regimenrelated toxicity in their series [21]. Infections due to myelosuppression remain the major cause of morbidity and mortality until
day 100. Management of febrile neutropenia was in accordance
with institutional guidelines. First-line i.v. antibiotic therapy consisted of piperacillin/tazobactam and amikacin. If a patient remained febrile after 48–72 hours, the regimen was changed to
imipenem/cilastatin, vancomycin, and amphotericin B (conventional). For afebrile patients, the initial antibiotic regimen was continued until the resolution of neutropenia. Our patients mainly
developed E. coli bloodstream infections (isolated from blood culture). Similar results were reported previously in HSCT recipients
in a retrospective study that investigated the effect of BSI on the
outcome of 246 allogeneic transplant recipients [22]. Gramnegative rods constituted 54% of the bacterial isolates. Hospitalacquired infections mainly due to Acinetobacter baumannii [23]
and carbapenem-resistant E. coli are an issue at our center. All
our transplants are performed in single rooms with HEPA filters.
Because of the increased frequency of possible fungal infections,
the hospital policy is to start amphotericin B early if the fever does
not resolve or if radiological signs suggestive of fungal infection are
present. Debilitating fungal infection was observed in 1 patient
only at our center and required surgical removal. Mycobacterium
tuberculosis infection has been reported occasionally in both autologous and allogeneic transplant recipients, possibly due to reactivation after the myelosuppression caused by conditioning therapy
[24]. Only 1 patient developed M. tuberculosis in our series.
Several observational and clinical trials have been conducted of
patients with NHL and HL. The 5-year survival after transplant in
these patients is approximately 50%–60% [25, 26]. The most common cause of treatment failure is relapse or disease progression.
This predominantly occurs in the first 2 years after the procedure.
Our cohort of patients with NHL and HL showed that after
a median 6 SE follow-up of 23.4 6 4.3 months (range, 14.8–32),
the overall survival was 70% and 71.4%, respectively. Most of our
patients with NHL had diffuse large B-cell lymphoma (DLBCL) in second remission. The role of ASCT during first remission as consolidative therapy in patients with DLBCL remains controversial and should
not be performed outside the clinical trial setting [27]. Bolwell et al.
[28] in 2002 reported a 5-year overall survival rate of 43% in patients
with NHL and high-grade histologic findings. Our results are comparable to their data. Philip et al., in a multicenter, prospective randomized trial, also compared autologous HSCT and nontransplant
salvage therapy and showed that autologous HSCT is the standard
of care for patients younger than 60 years old with chemotherapysensitive relapsed or primary refractory aggressive NHL [29].
High-dose therapy with melphalan (200 mg/m2), followed by
ASCT in combination with novel agents is considered the standard
of care for patients with newly diagnosed multiple myeloma. In
our cohort of patients with MM, all were younger than 65 years
old. The median age 6 SD was 48 6 7.5 years (range, 32–55). A
recent, open-label, randomized phase 3 trial comparing highdose melphalan followed by ASCT and melphalan, prednisolone,
and lenalidomide showed significantly longer progression-free
and overall survival [30]. Other studies of younger patients have
shown overall survival rates ranging from 48.3% to 66% [31, 32].
Compared with this, our patients did relatively better, with an
overall survival of approximately 93%. All these patients were receiving maintenance therapy with either thalidomide or lenalidomide at the last follow-up visit.
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In a retrospective analysis, the median cost of autologous
transplant at our institution was approximately $20,000 (range,
$10,000–$35,000). This cost includes the cost of chemotherapy,
stem cell/bone marrow harvest, antibiotic usage, blood and/or blood
product transfusion and growth factor support, the daily bed and investigation charges, and the consultation fees. The cost of clinic visits
and subsequent admissions was omitted. Our data clearly show that
the cost of stem cell transplant is less expensive in Pakistan than in
developed countries with similar success rates. The major contributing factors to the cost and overall mortality include debilitating infections and regimen-related toxicities that prolonged the hospital stay.

CONCLUSION
We observed survival rates similar to those in the international data
for non-Hodgkin’s and Hodgkin’s lymphoma. Higher response rates
and reduced morbidity and mortality in patients with multiple myeloma resulted from their younger age and proper case selection.
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